SCHEMBL1732896

SCHEMBL1732896

CCC(Oc1cccc2[nH]c3ccccc3c12)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 6/20 0.46
DNM1 Q05193 2/20 0.46
PPARG P37231 2/20 0.46
PPARA Q07869 1/20 0.46
MAPT P10636 4/20 0.45
LMNA P02545 1/20 0.45
CYP3A4 P08684 1/20 0.45
ABCG2 Q9UNQ0 1/20 0.45
TLR4 O00206 5/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
ADRB1 P08588 2/20 0.42
ADRB3 P13945 2/20 0.42
IMPDH2 P12268 1/20 0.42
IMPDH1 P20839 1/20 0.42
DRD2 P14416 3/20 0.41
KMT2A Q03164 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
KDM4E B2RXH2 2/20 0.41
SLC22A2 O15244 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1733321 0.90 PPARG (0.47) ADRB2DNM1PPARGPPARAMAPT
SCHEMBL1732953 0.88 PPARG (0.44) ADRB2DNM1PPARGPPARAMAPT
SCHEMBL12154504 0.87 ADRB2 (0.42) ADRB2DNM1PPARGPPARAMAPT
SCHEMBL1733266 0.86 ADRB3 (0.43) ADRB2DNM1PPARGMAPTLMNA
SCHEMBL1733165 0.83 KMT2A (0.54) ADRB2DNM1PPARGPPARAMAPT
SCHEMBL1731305 0.80 ADRB2 (0.47) ADRB2DNM1PPARGPPARAMAPT
SCHEMBL1732873 0.78 IMPDH2 (0.44) ADRB2DNM1PPARGPPARAMAPT
SCHEMBL8821208 0.77 PPARG (0.67) PPARGPPARAKMT2ATDP1KDM4E
SCHEMBL8935882 0.77 PPARG (0.67) PPARGPPARAKMT2ATDP1KDM4E
SCHEMBL9754501 0.77 PPARG (0.47) ADRB2PPARGPPARAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329913-B2 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8329913-B2 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8329913-B2 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1852433-B1 CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZERIA PHARM CO LTD (JP) 2011-11-23 EP disclosed
EP-1852433-B1 CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ZERIA PHARM CO LTD (JP) 2011-11-23 EP disclosed
US-20100286210-A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2010-11-11 US disclosed
US-20100286210-A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2010-11-11 US disclosed
US-20100286210-A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof ZERIA PHARMACEUTICAL CO., LTD. (JP) 2010-11-11 US disclosed
EP-1852433-A1 CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Zeria Pharmaceutical Co., Ltd. (JP) 2007-11-07 EP disclosed
EP-1852433-A1 CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Zeria Pharmaceutical Co., Ltd. (JP) 2007-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286210-A1 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof CEL, LIPC, CES1 ADRB2 566/4885DNM1 2604/4885PPARG 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.